Background <p>Immune checkpoint inhibitors (ICIs) have been proven to be one of the most promising and effective immunotherapies; however, their efficacy in colorectal cancer (CRC) remains significantly limited. Therefore, understanding the mechanism of resistance to ICIs therapy in CRC patients is of great significance for the development of new anti-tumor immunotherapy targets.</p> Methods <p>Ccl7 myeloid cell-specific knockout mice and MC38…
Macrophage CCL7 promotes resistance to immunotherapy for colorectal cancer by regulating the infiltration of macrophages and CD8+ T cells
Journal for ImmunoTherapy of Cancer | | Chen, Y., Liu, X., Chen, J., Kuang, L., Zhang, N., Li, D., Zhao, D., Xue, D., Lei, J., Zhang, J., Li, Y., Wu, L.
Topics: colorectal-cancer, immunotherapy, research
Read the full article at Journal for ImmunoTherapy of Cancer